Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Walgreens stock (NASDAQ:WBA) gained momentum following renewed speculation about a potential acquisition by private equity ...

Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...